Earnings summaries and quarterly performance for ICU MEDICAL INC/DE.
Executive leadership at ICU MEDICAL INC/DE.
Board of directors at ICU MEDICAL INC/DE.
Research analysts who have asked questions during ICU MEDICAL INC/DE earnings calls.
Michael Toomey
Jefferies
4 questions for ICUI
Also covers: ALUR
Brett Fishbin
KeyBanc Capital Markets
3 questions for ICUI
Also covers: ALC, COO, INSP +6 more
Jayson Bedford
Raymond James
3 questions for ICUI
Also covers: AXGN, DXCM, IART +7 more
LS
Lawrence Solow
CJS Securities, Inc.
2 questions for ICUI
Also covers: BTSG, CDRE, CLH +13 more
Mike Matson
Needham & Company, LLC
2 questions for ICUI
Also covers: CNMD, ENOV, ESTA +16 more
CS
Charles Strauzer
CJS Securities
1 question for ICUI
Also covers: CMCO, DFIN, DLX +2 more
CS
Charlie Strazza
CJS Securities
1 question for ICUI
EF
Eric Fleming
Raymond James
1 question for ICUI
KS
Kristen Stewart
CL King & Associates
1 question for ICUI
Also covers: AVNS, CNMD, HAE +3 more
Michael Matson
Needham & Company
1 question for ICUI
Also covers: AORT, ATRC, CNMD +22 more
WC
Will Corner
KeyBanc Capital Markets
1 question for ICUI
Recent press releases and 8-K filings for ICUI.
ICU Medical Provides Business Update and Financial Outlook
ICUI
Guidance Update
Revenue Acceleration/Inflection
Share Buyback
- ICU Medical's Chairman and CEO, Vivek Jain, noted a healthy market environment with strong hospital volumes and no significant capital constraints.
- The consumables business continues to show strong, durable growth, with legacy products compounding at 5-6% annually, driven by volumes, market share gains, and innovation.
- The company's pump replacement cycle for its existing 20% U.S. LVP install base is expected to commence in late 2026 or early 2027, presenting a multi-year opportunity.
- ICU Medical projects a $25 million tariff impact for 2025 and anticipates the 2026 impact to be between this amount and double it, considering operational adjustments and inflation.
- The company is confident in achieving 45% pre-tariff gross margins over the next two years, having already recovered approximately 300 basis points of a 500 basis point gap to reach 41% (43% pre-tariff) in the most recent quarter. Once debt is reduced, stock buybacks are the preferred capital return strategy.
Dec 4, 2025, 6:00 PM
ICU Medical Discusses Market, Growth, and Financial Targets
ICUI
Revenue Acceleration/Inflection
Guidance Update
Share Buyback
- ICU Medical (ICUI) observes a healthy market environment with increasing volumes and no decrease in hospital census. The consumables business continues to show strong growth, driven by volume and market share gains.
- The company anticipates a significant pump replacement cycle for its existing install base to begin in late 2026 or early 2027, with each point of market share in the LVP business valued at $8 million-$10 million annually in revenue for a decade.
- ICU Medical is targeting a 45% pre-tariff gross margin within the next two years, an increase from 41% (post-tariff) in the most recent quarter, partly achieved through the divestment of its low-margin IV Solutions business.
- The company expects a $25 million tariff burden this year, but advises against annualizing this for 2026 due to potential offsets and headwinds.
- ICU Medical's capital allocation strategy prioritizes reducing debt to two times leverage, after which share buybacks are the preferred approach.
Dec 4, 2025, 6:00 PM
ICU Medical Reports Q3 CY2025 Results and Raises Full-Year Guidance
ICUI
Earnings
Guidance Update
M&A
- ICU Medical reported Q3 CY2025 revenue of roughly $533–$537 million, which was down approximately 8.9% year-over-year but exceeded Street estimates, and delivered non-GAAP EPS of $2.03.
- The company raised its full-year profitability targets, with adjusted EPS guidance implying roughly $7.35–$7.65 (midpoint ≈ $7.50) and adjusted EBITDA guidance near $395–$405 million.
- ICU Medical is actively prioritizing deleveraging and interest-cost reduction, having made $273 million in year-to-date debt principal repayments and refinancing to lower annual interest expense by roughly $2 million.
- The company reshaped its portfolio via a May 2025 joint venture with Otsuka to focus on higher-margin consumables and infusion systems, with underlying segment performance showing Consumables revenue up ~8% and IV Systems revenue up ~9%.
Nov 7, 2025, 1:02 PM
ICU Medical announces Q3 2025 results and updates 2025 guidance
ICUI
Earnings
Guidance Update
M&A
- ICU Medical reported Q3 2025 Adjusted Revenue of $533 million, representing an 8% year-over-year decline but a 5% year-over-year organic growth.
- The company updated its 2025 full-year guidance for Adjusted EBITDA to a range of $395 million to $405 million and Adjusted EPS to $7.35 to $7.65.
- The Vital Care segment experienced a 52% year-over-year decline in Q3 2025 revenue, largely influenced by the joint venture transaction, with its 2025 full-year guidance projecting ~ (35%) FXN / Flat organic revenue.
Nov 6, 2025, 9:30 PM
ICU Medical Reports Q3 2025 Financial Results and Provides Q4 Outlook
ICUI
Earnings
Guidance Update
Revenue Acceleration/Inflection
- ICU Medical reported Q3 2025 revenue of $533 million, reflecting 5% organic growth but a -8% reported year-over-year decline due to the deconsolidation of the IV solutions business.
- For Q3 2025, the company achieved an adjusted EBITDA of $106 million and EPS of $2.03.
- The adjusted gross margin for Q3 2025 was 41%, positively impacted by the IV solutions deconsolidation and a $4 million benefit from settling an Italian payback liability, but reduced by $9 million in tariff expenses.
- The company has repaid $273 million in principal year to date.
- For Q4 2025, ICU Medical anticipates gross margin to be in the range of 40%-41%, with operating expenses projected at approximately 25.5% of revenue, and expects full-year tariff expense to be around $25 million.
Nov 6, 2025, 9:30 PM
ICU Medical Announces Third Quarter 2025 Results and Updates Fiscal Year 2025 Guidance
ICUI
Earnings
Guidance Update
- ICU Medical, Inc. reported Q3 2025 revenue of $537.0 million, a decrease from $589.1 million in the same period in the prior year.
- The company's GAAP net loss for Q3 2025 was $(3.4) million, or $(0.14) per diluted share, an improvement from a GAAP net loss of $(33.0) million, or $(1.35) per diluted share, in Q3 2024.
- Adjusted diluted earnings per share for Q3 2025 was $2.03, up from $1.59 in Q3 2024, and Adjusted EBITDA was $105.9 million compared to $94.8 million in Q3 2024.
- ICU Medical updated its Fiscal Year 2025 guidance, revising the GAAP net loss estimate to a range of $(8) million to $0 million and increasing the adjusted EBITDA estimate to a range of $395 million to $405 million.
Nov 6, 2025, 9:10 PM
ICU Medical Announces Third Quarter 2025 Results and Updates Fiscal Year 2025 Guidance
ICUI
Earnings
Guidance Update
- ICU Medical reported third quarter 2025 revenue of $537.0 million.
- For Q3 2025, the company recorded a GAAP net loss of $(3.4) million, or $(0.14) per diluted share, with adjusted diluted earnings per share of $2.03.
- Adjusted EBITDA for the third quarter of 2025 was $105.9 million.
- The company updated its Fiscal Year 2025 guidance, revising the estimated GAAP net loss to a range of $(8) million to $0 million and GAAP diluted loss per share to $(0.30) to $0.00.
- Full-year 2025 guidance for adjusted EBITDA was updated to a range of $395 million to $405 million, and adjusted diluted earnings per share to $7.35 to $7.65.
Nov 6, 2025, 9:05 PM
SeaStar Medical Highlights Cost Savings of QUELIMMUNE Therapy
ICUI
New Projects/Investments
Revenue Acceleration/Inflection
- SeaStar Medical announced a health economic analysis published in the Journal of Medical Economics (IJME) estimating $69,146 in cost savings per hospitalization for pediatric Acute Kidney Injury (AKI) patients treated with its QUELIMMUNE therapy compared to standard continuous renal replacement therapy (CRRT).
- These projected savings, driven by a reduced hospital length of stay of approximately 3 days and improved survival, are estimated to offset the cost of the QUELIMMUNE therapy, potentially leading to no out-of-pocket costs for institutions for a median of 6 days of treatment.
- The QUELIMMUNE therapy was approved by the US FDA in 2024 for pediatric AKI due to sepsis. Clinical studies showed a 77% survival rate in treated patients, representing a potential ~50% reduction in loss of life compared to historical data.
- The company notes that highly regarded children's medical centers have already adopted the QUELIMMUNE therapy, with this new economic data expected to support broader adoption.
Sep 2, 2025, 12:24 PM
SeaStar Medical Announces Nasdaq Listing Compliance
ICUI
Delisting/Listing Issues
Product Launch
New Projects/Investments
- SeaStar Medical (ICUI) has received confirmation from Nasdaq that it has met the minimum $2.5 million stockholders’ equity requirement and other listing criteria, resulting in the closure of the previously disclosed listing matter.
- The company can now focus on commercializing QUELIMMUNE, which was approved in February 2024 and showed a 77% survival rate in treated patients.
- SeaStar Medical is also conducting the NEUTRALIZE-AKI pivotal trial for its Selective Cytopheretic Device (SCD) therapy in adults with Acute Kidney Injury (AKI).
- The SCD therapy has received Breakthrough Device Designation from the FDA for four therapeutic indications.
Jul 2, 2025, 8:25 PM
ICU Medical Announces Q1 2025 Results
ICUI
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Revenues increased to $604.7M in Q1 2025 vs $566.7M in Q1 2024, driven by strong contributions from Consumables, Infusion Systems, and Vital Care .
- Total ICU’s adjusted revenue reached $599M, with detailed segmented results for Systems and Vital Care .
- GAAP net loss narrowed to $(15.5)M (or $(0.63) per diluted share) compared to $(39.5)M (or $(1.63) per share) in the prior year .
- Adjusted diluted EPS rose to $1.72 and adjusted EBITDA reached $99.4M, reflecting enhanced operational performance .
- Updated guidance projects Adjusted EBITDA of $380m to $405m and maintains Adjusted EPS guidance of $6.55 to $7.25 with key assumptions on currency and SG&A .
May 8, 2025, 8:30 PM
Quarterly earnings call transcripts for ICU MEDICAL INC/DE.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more